FDA approves alpelisib for metastatic breast cancer

On May 24, 2019, the Food and Drug Administration approved alpelisib (PIQRAY, Novartis Pharmaceuticals Corporation) in combination with fulvestrant for postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advan

Source: FDA Center for Drug Evaluation and Research - What's New - May 28, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news